Gene could hold key to treating Parkinson's disease
Researchers at King’s College London have identified a new gene linked to nerve function, which could provide a treatment target for ‘switching off’ the gene in people with neurodegenerative diseases such as Parkinson’s disease.
Parkinson’s disease affects approximately 7-10 million people worldwide and is characterised by progressive loss of motor function, psychiatric symptoms and cognitive impairment.
Current treatments for Parkinson’s only treat symptoms of the disease rather than its underlying causes, so these new findings in fruit flies could lead to novel preventative treatments if replicated in humans.
Previous research suggests that defects in mitochondria, which are tiny ‘batteries’ in cells that provide energy, play an important role in a number of diseases that affect the nervous system, including Parkinson’s. However, until now the neuronal processes underlying the development of these conditions were unknown.
The study, published today in PNAS, discovered that damaged mitochondria in fruit flies produce a signal which stops nerve cells from working. A gene called HIFalpha was found to regulate the nerve signals from damaged mitochondria and, when this gene was ‘switched off’ by the research team, nerve function in flies with Parkinson’s disease was restored. By deactivating the HIFalpha gene, the early failure of nerve cells caused by mitochondrial damage was prevented.
An identical effect was observed in flies with Leigh syndrome, a rare neurological disorder caused by a severe mitochondrial defect, which typically arises in the first year of life in humans.
As the HIFalpha gene is also found in humans, this new finding could pave the way for new treatments in the future, according to the study authors.
Dr Joseph Bateman from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, said: ‘Like their human counterparts flies with Parkinson’s disease progressively lose motor function, which includes a negative impact on their ability to climb. Remarkably, we found that switching off a particular gene dramatically improved their motor function and climbing ability.
‘The biggest surprise from our work is that damaged mitochondria produce a signal that actively prevents nerve cells from working properly. Thanks to this study we now have a much better understanding of how nerve cells function, which could transform the way in which neurological diseases such as Parkinson’s are understood and treated.’
Claire Bale, Head of Research Communications at Parkinson’s UK, said: ‘Understanding how subtle changes in our genes may trigger brain cell death is one of the most promising avenues for the development of new treatments for Parkinson’s.
‘This discovery adds a new piece to the intricate jigsaw puzzle of genetic factors that play a part in Parkinson’s.’
This research was carried out in collaboration with Dr Sean Sweeney of the Department of Biology, University of York and Dr Marc Dionne of the Department of Life Sciences, Imperial College London.
The study was part-funded by the Wellcome Trust, the Biotechnology and Biological Sciences Research Council (BBSRC) and a Biomedical Research Studentship / Fellowship to study co-author Olivia Duncan from the National Institute for Health Research (NIHR) Biomedical Research Centre [and Dementia Unit] at South London and Maudsley NHS Foundation Trust and King's College London.
Notes to editors
Paper reference: Cagin, U et al (2015) Mitochondrial retrograde signalling regulates neuronal function PNAS
For further media information please contact Jack Stonebridge, Press Officer, Institute of Psychiatry, Psychology & Neuroscience, King’s College London on +44 (0) 20 7848 5377 or jack.stonebridge@kcl.ac.uk.
For further information about King’s visit our ‘King’s in Brief’ page.